Marc Buyse

发表

Methodology of Adaptive Randomization

Marc Buyse, 2015 .

Open science: The open clinical trials data journey

Marc Buyse, Frank Rockhold, Christina Bromley, 2019, Clinical trials.

Notation and Motivating Studies

Geert Molenberghs, Marc Buyse, Tomasz Burzykowski, 2005 .

Artificial neural networks

Marc Buyse, Pascal Piedbois, M. Buyse, 1997, The Lancet.

A unifying approach for surrogate marker validation based on Prentice's criteria

Geert Molenberghs, Helena Geys, Tony Vangeneugden, 2006, Statistics in medicine.

Prentice's Approach and the Meta‐Analytic Paradigm: A Reflection on the Role of Statistics in the Evaluation of Surrogate Endpoints

Geert Molenberghs, Ziv Shkedy, José Cortiñas Abrahantes, 2004, Biometrics.

A Poisson approach to the validation of failure time surrogate endpoints in individual patient data meta-analyses

Tomasz Burzykowski, Federico Rotolo, Marc Buyse, 2019, Statistical methods in medical research.

Surrogate threshold effect: an alternative measure for meta‐analytic surrogate endpoint validation

Marc Buyse, Tomasz Burzykowski, M. Buyse, 2006, Pharmaceutical statistics.

Validation of Surrogate Endpoints in Multiple Randomized Clinical Trials with Discrete Outcomes

Geert Molenberghs, Helena Geys, Marc Buyse, 2002 .

A new method to analyze randomized clinical trials

Marc Buyse, 2010 .

Evaluation of treatment efficacy using a Bayesian mixture piecewise linear model of longitudinal biomarkers

Brian Neelon, Marc Buyse, Dai Feng, 2015, Statistics in medicine.

Letter to the editor: artificial neural networks

Marc Buyse, P. Piedbois, 1997 .

Surrogate end points: when should they be used?

Geert Molenberghs, Tomasz Burzykowski, Marc Buyse, 2013 .

A Statistical Approach to Risk-Based Monitoring

Marc Buyse, M. Buyse, 2014 .

Evaluation of Surrogate Endpoints

Geert Molenberghs, Marc Buyse, Tomasz Burzykowski, 2006, Handbook of Statistical Methods for Randomized Controlled Trials.

Generalized Pairwise Comparisons

Marc Buyse, M. Buyse, 2019, Wiley StatsRef: Statistics Reference Online.

Common pitfalls in statistical analysis: The perils of multiple testing

Priya Ranganathan, Marc Buyse, C. S. Pramesh, 2016, Perspectives in clinical research.

Generalized Pairwise Comparisons for Prioritized Outcomes

Marc Buyse, Julien Péron, M. Buyse, 2021 .

Adjuvant trastuzumab in HER2-positive breast cancer.

Marc Buyse, Arlene Chan, Marek Pawlicki, 2011, The New England journal of medicine.

Data fraud in clinical trials.

Marc Buyse, Stephen L George, M. Buyse, 2015, Clinical investigation.

Data sharing, year 1--access to data from industry-sponsored clinical trials.

Bartha M. Knoppers, Marc Buyse, Brian L. Strom, 2014, The New England journal of medicine.

Statistical Validation of Surrogate Endpoints: Problems and Proposals

Geert Molenberghs, Tomasz Burzykowski, Helena Geys, 2000 .

Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis.

Satoshi Morita, Yasuo Ohashi, Junichi Sakamoto, 2013, Journal of the National Cancer Institute.

The validation of surrogate end points by using data from randomized clinical trials: a case‐study in advanced colorectal cancer

Geert Molenberghs, Tomasz Burzykowski, Marc Buyse, 2004 .

Simplified hierarchical linear models for the evaluation of surrogate endpoints

Geert Molenberghs, Russell D. Wolfinger, José Cortiñas Abrahantes, 2003 .

End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group.

Daniel J Sargent, Greg Yothers, Daniel G Haller, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis

Geert Molenberghs, Tomasz Burzykowski, Marc Buyse, 2000, The Lancet.

Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial

Marc Buyse, Stella Mook, Jan Bogaerts, 2006, Nature Clinical Practice Oncology.

Towards validation of statistically reliable biomarkers

Marc Buyse, M. Buyse, 2007 .

Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial.

Marc Buyse, Pascal Piedbois, Thierry Andre, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer

Yasuo Ohashi, Junichi Sakamoto, Tomasz Burzykowski, 2009 .

Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set.

Brian Bot, Greg Yothers, Qian Shi, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer.

Tomasz Burzykowski, Arturo Molina, Marc Buyse, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Statistical challenges in the evaluation of surrogate endpoints in randomized trials.

Geert Molenberghs, Tomasz Burzykowski, Helena Geys, 2002, Controlled clinical trials.

Cyclophosphamide Plus Cisplatin Versus Cyclophosphomide, Doxorubicin, and Cisplatin Chemotherapy of Ovarian-carcinoma - a Metaanalysis

Marc Buyse, M. Buyse, 1991 .

Validation of a longitudinally measured surrogate marker for a time-to-event endpoint

Geert Molenberghs, Luc Bijnens, Tomasz Burzykowski, 2003 .

Statistical evaluation of surrogate endpoints with examples from cancer clinical trials

Geert Molenberghs, Tomasz Burzykowski, Marc Buyse, 2016, Biometrical journal. Biometrische Zeitschrift.

Ensuring trial validity by data quality assurance and diversification of monitoring methods

Douglas G Altman, Marc Buyse, Frank E Harrell, 2008, Clinical trials.

Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study.

John R. Mackey, Marc Buyse, Arlene Chan, 2009 .

Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis.

Satoshi Morita, Yasuo Ohashi, Junichi Sakamoto, 2013, European journal of cancer.

Improving public health by improving clinical trial guidelines and their application

Adam Cohen, Jeroen J. Bax, Marc Buyse, 2017, European heart journal.

A statistical approach to central monitoring of data quality in clinical trials

Tomasz Burzykowski, Catherine Legrand, Marc Buyse, 2012, Clinical trials.

Integrating biomarkers in clinical trials

Daniel J Sargent, Marc Buyse, Stefan Michiels, 2011, Expert review of molecular diagnostics.

R2: a useful measure of model performance when predicting a dichotomous outcome by A. Ash and M. Schwartz, Statistics in Medicine, 18, 375–384 (1999)

Marc Buyse, 2000 .

Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials.

Daniel J Sargent, Daniel G Haller, Marc Buyse, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis.

Satoshi Morita, Yasuo Ohashi, Junichi Sakamoto, 2013, Journal of the National Cancer Institute.

GENERAL THORACIC SURGERY LONG-TERM RESULTS OF LUNG METASTASECTOMY : PROGNOSTIC ANALYSES BASED ON 5206 CASES The International Registry of Lung Metastases

Ugo Pastorino, Marc Buyse, Philippe Girard, 2004 .

Multi-centre independent validation of a gene prognostic signature for patients with node-negative breast cancer (BC) - final results

Marc Buyse, Mauro Delorenzi, Christos Sotiriou, 2005 .

Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission

Marc Buyse, Stefan Michiels, M. Buyse, 2011, Haematologica.

Transforming genomic grade index (GGI) into a user-friendly qRT-PCR tool which will assist clinicians and patients in optimizing treatment of early breast cancer (BC)

Gianluca Bontempi, Marc Buyse, Benjamin Haibe-Kains, 2007 .

Progression-free survival (PFS) as a surrogate for overall survival (OS) in patients with advanced colorectal cancer: An analysis of 3159 patients randomized in 11 trials

Tomasz Burzykowski, J. P. Pignon, Kevin Carroll, 2005 .

Biological mechanisms that trigger breast cancer (BC) tumor progression are molecular subtype dependent

Gianluca Bontempi, Marc Buyse, Mauro Delorenzi, 2007 .

Individual- and trial-level surrogacy in colorectal cancer

Tomasz Burzykowski, Kevin Carroll, Marc Buyse, 2008, Statistical methods in medical research.

Adaptive Randomization of Neratinib in Early Breast Cancer.

Tomasz Burzykowski, Marc Buyse, M. Buyse, 2016, The New England journal of medicine.

Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.

Tomasz Burzykowski, Marc Buyse, Laura Biganzoli, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes

Gianluca Bontempi, Marc Buyse, Mauro Delorenzi, 2008, Clinical Cancer Research.

Comprehensive molecular analysis of several prognostic signatures using molecular indices related to hallmarks of breast cancer: proliferation index appears to be the most significant component of all signatures

Gianluca Bontempi, Marc Buyse, Mauro Delorenzi, 2006 .

Exploring and validating surrogate endpoints in colorectal cancer

Junichi Sakamoto, Tomasz Burzykowski, Greg Yothers, 2008, Lifetime data analysis.

Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data.

Tomasz Burzykowski, Marc Buyse, Stefan Michiels, 2009, The Lancet. Oncology.

Comparison of prognostic gene expression signatures for breast cancer

Gianluca Bontempi, Marc Buyse, Benjamin Haibe-Kains, 2008, BMC Genomics.

Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy--an Aide et Recherche en Cancerologie Digestive Group Study.

Daniel J Sargent, Qian Shi, Marc Buyse, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The ARCAD clinical trials program: an update and invitation.

Daniel J Sargent, Marc Buyse, Alastair Matheson, 2012, The oncologist.

Multifactorial approach to predicting resistance to anthracyclines.

Yuan Qi, Gianluca Bontempi, Marc Buyse, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.